Skip to main content

Advertisement

Table 2 Differences in the number of patients receiving allogeneic blood products, coagulation factors and resuscitation fluids (independent of amount) between the propensity score matched groups (LUKS: Cantonal Hospital Lucerne, USZ: University Hospital Zurich)

From: Comparison of two different coagulation algorithms on the use of allogenic blood products and coagulation factors in severely injured trauma patients: a retrospective, multicentre, observational study

  USZ (n = 172) LUKS (n = 172) OR (95% CI) p-value
RBC 20 (11.6%) 51 (29.7%) 3.2 (1.8–5.7) < 0.001
FFP 4 (2.3%) 9 (5.2%) 2.3 (0.7–7.7) 0.16
PLT 10 (5.8%) 6 (3.5%) 0.6 (0.2–1.6) 0.31
TXA 76 (44.2%) 66 (28.6%) 0.8 (0.5–1.2) 0.29
Fibrinogen 42 (24.4%) 59 (34.3%) 1.6 (1.0–2.6) 0.04
PCC 17 (9.9%) 41 (23.8%) 2.9 (1.5–5.3) 0.001
Factor XIII 15 (8.7%) 6 (3.5%) 0.4 (0.1–1.0) 0.04
Starch 5 (2.9%) 37 (21.5%) 9.2 (3.5–23.9) < 0.001
Gelatin 47 (27.3%) 27 (15.7%) 0.5 (0.3–0.8) 0.009
  1. Data reported as frequency (n) with percentage (%). Odds ratio (OR) with 95% confidence intervals (CI) and p-values were calculated using logistic regression. Level of significance 0.05
  2. FFP fresh frozen plasma, FXIII coagulation factor XIII, PCC 4 factor prothrombin complex concentrate, PLT platelet concentrate, RBC red blood cell concentrate, TXA tranexamic acid